Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: a large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases

Published: 25 August 2022| Version 1 | DOI: 10.17632/jvs782kvw8.1
Lucie Heinzerling


This dataset contains demographic, clinical, and health-related quality of life (HRQoL) data from 2905 patients including 200 cancer patients after immune checkpoint inhibitor (ICI) cessation and 2705 patients with a wide variety of autoimmune diseases.


Steps to reproduce

Within this multicenter, cross-sectional survey study data were collected questionnaire-based in cancer patients (ICI-patients) ≥ 18 years of age who had received at least one dose of ICI with ≥ 12 weeks since ICI discontinuation. Patients with autoimmune diseases (AI-patients) were ≥ 18 years, had at least one autoimmune disease and had never received ICI. ICI-patients were recruited in three skin cancer centers and via support groups. AI-patients were recruited in an outpatient clinic for internal medicine and via support groups.


Immunology, Cancer, Autoimmunity, Autoimmune Disorder, Immune Disorder, Immunotherapy, Side Effect, Adverse Event, Melanoma, Quality of Life, Immune Checkpoint Blockade, Immunotherapy of Skin Cancer, Immune Checkpoint Inhibitor